Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development

Thumbnail Image
Download
Name

140281.3-20260401120844-covered-4fa089109ce452e764bbb8648b44a723.pdf

Description
Published version
Size

22.42 MB

Format

Adobe PDF

Checksum (MD5)

6dae891377296ae672f67e41c6cb3b18

Thumbnail Image
Download
Name

205886.1-20260326164445-covered-4fa089109ce452e764bbb8648b44a723.pdf

Description
Corrigendum
Size

3.37 MB

Format

Adobe PDF

Checksum (MD5)

4282d0a453c9b70da222d48e3a03d8d4

Author(s)
Katkeviciute, Egle
•
Hering, Larissa
•
Montalban-Arques, Ana
•
Busenhart, Philipp
•
Schwarzfischer, Marlene
•
Manzini, Roberto
•
Conde, Javier
•
Atrott, Kirstin
•
Lang, Silvia
•
Rogler, Gerhard
Date Issued
October 1, 2020
Journal
Journal of Clinical Investigation
Publisher
American Society for Clinical Investigation
Version
Final published version
Abstract
Protein tyrosine phosphatase nonreceptor type 2 (PTPN2) recently emerged as a promising cancer immunotherapy target. We set out to investigate the functional role of PTPN2 in the pathogenesis of human colorectal carcinoma (CRC), as its role in immune-silent solid tumors is poorly understood. We demonstrate that in human CRC, increased PTPN2 expression and activity correlated with disease progression and decreased immune responses in tumor tissues. In particular, stage II and III tumors displayed enhanced PTPN2 protein expression in tumor-infiltrating T cells, and increased PTPN2 levels negatively correlated with expression of PD-1, CTLA4, STAT1, and granzyme A. In vivo, T cell- and DC-specific PTPN2 deletion reduced tumor burden in several CRC models by promoting CD44+ effector/memory T cells, as well as CD8+ T cell infiltration and cytotoxicity in the tumor. In direct relevance to CRC treatment, T cell-specific PTPN2 deletion potentiated anti-PD-1 efficacy and induced antitumor memory formation upon tumor rechallenge in vivo. Our data suggest a role for PTPN2 in suppressing antitumor immunity and promoting tumor development in patients with CRC. Our in vivo results identify PTPN2 as a key player in controlling the immunogenicity of CRC, with the strong potential to be exploited for cancer immunotherapy.
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1172/jci140281
PrivacyPermissionsAccessibilityContact us
Notify us about copyright concerns.